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CLINICAL RESEARCH
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Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-antagonist oral anticoagulants
(NOACs) compared with warfarin. The aim of this study was to assess the effectiveness and safety of dabigatran (direct




In this observational study, we evaluated all consecutive patients who started anticoagulation because of AF in our out-
patient clinic from 2010 to 2013. Data were collected from electronic patient charts. Primary outcomes were stroke or
systemic embolism and major bleeding. Propensity score matching was applied to address the non-randomized design.
In total, 920 consecutive AF patients were enrolled (442 dabigatran, 478 acenocoumarol), of which 2 × 383 were avail-
able for analysis after propensity score matching. Mean follow-up duration was 1.5+ 0.56 year. The mean calculated
stroke risk according to the CHA2DS2-VASc score was 3.5%/year in dabigatran vs. 3.7%/year acenocoumarol-treated
patients. The actual incidence rate of stroke or systemic embolism was 0.8%/year [95% confidence interval (CI):
0.2–2.1] vs. 1.0%/year (95% CI: 0.4–2.1), respectively. Multivariable analysis confirmed this lower but non-significant
risk in dabigatran vs. acenocoumarol after adjustment for the CHA2DS2-VASc score [hazard ratio (HR)dabigatran ¼ 0.72,
95% CI: 0.20–2.63, P ¼ 0.61]. According to the HAS-BLED score, the mean calculated bleeding risk was 1.7%/year in
both groups. Actual incidence rate of major bleeding was 2.1%/year (95% CI: 1.0–3.8) in the dabigatran vs. 4.3%/year
(95% CI: 2.9–6.2) in acenocoumarol. This over 50% reduction remained significant after adjustment for the HAS-BLED
score (HRdabigatran ¼ 0.45, 95% CI: 0.22–0.93, P ¼ 0.031).
Conclusion In ‘real-world’ patients with AF, dabigatran appears to be as effective, but significantly safer than acenocoumarol.
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Keywords Atrial fibrillation † Anticoagulation † Acenocoumarol † Dabigatran † Stroke † Bleeding
Introduction
Stroke is a very serious and common complication of atrial fibrillation
(AF), which is the most prevalent clinically significant cardiac arrhyth-
mia.1 Effective prevention of stroke by means of oral anticoagulation
therapy is vital.2 Until recently, the vitamin K antagonists (VKAs), such
as warfarin and acenocoumarol, were the only available oral anticoa-
gulants. These drugs effectively reduce the risk of stroke in patients
with AF, but increase the risk of major bleeding, especially intracranial
hemorrhage.3 In addition, the use of VKAs is cumbersome because of
multiple food and drug interactions and a small therapeutic range, ne-
cessitating frequent laboratory monitoring and dose adjustments. In
* Corresponding author: Tel: +3150 5245801; fax: +3150 5245802. E-mail address: r.tieleman@mzh.nl
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Europace (2016) 18, 1319–1327
doi:10.1093/europace/euv397





the Netherlands, anticoagulation therapy is monitored by well-
organized anticoagulation clinics, called the Thrombosis Service.
The non-vitamin-K-antagonist oral anticoagulants (NOACs),
both the direct thrombin inhibitors (dabigatran) and factor Xa
blockers (rivaroxaban, apixaban, edoxaban), have emerged as an al-
ternative for anticoagulation therapy with VKAs.4–8 They have pre-
dictable pharmacokinetics without the need for routine monitoring
like VKAs. Secondly, they have a low potential for food and drug in-
teractions. Finally, and probably most important, they have an im-
proved efficacy/safety ratio.4 Randomized controlled trials showed
non-inferior or superior efficacy and safety results of the NOACs
compared with warfarin.5–8 For this reason, the ESC guideline for
the management of AF accomplished by the European Society of
Cardiology (ESC) was updated in 2012. This guideline now recom-
mends NOACs as broadly preferable to VKAs in the vast majority of
patients with non-valvular AF.9
In all randomized controlled trials, warfarin was used as the
comparator of the different NOACs.5–8 However, in different parts
of the world, other coumarin derivatives are widely used such as ace-
nocoumarol and phenprocoumon. Although the working mechanism
is similar, there are some important pharmacokinetic differences be-
tweenwarfarin, acenocoumarol, and phenprocoumon. In comparison
with warfarin, acenocoumarol has a very short elimination half-life of
1.8 h for S-acenocoumarol and 6.6 h for R-acenocoumarol, where
warfarin has an elimination half-life of 24–33 h for S-warfarin and
35–58 h for R-warfarin. Phenprocoumon has the longest elimination
half-life of 110–130 h.10 The primary aim of the present study was to
assess the effectiveness and safety of dabigatran vs. the VKA acenocou-
marol in patients with AF in daily clinical practice.
Methods
Study design
This was a retrospective, single-centre, observational study conducted
in the Martini Hospital Groningen, the Netherlands, comparing the ef-
fectiveness and safety of dabigatran with acenocoumarol in consecutive
patients with AF in daily clinical practice.
Study population
We evaluated all consecutive patients who started with oral anticoagu-
lation therapy because of non-valvular AF and an increased risk for
stroke according to the CHA2DS2-VASc score (score ≥1 point) in
our outpatient clinic from 1 January 2010 till 31 December 2012. Pa-
tients were collected by a computerized search in the electronic pa-
tients registry for the combination of the diagnosis code ‘atrial
fibrillation’ with initiated medication use of acenocoumarol or dabiga-
tran within these years. Atrial fibrillation was confirmed on a 12-lead
electrocardiogram. For the purpose of this study, all patients were allo-
cated to either the acenocoumarol or the dabigatran study group. Pa-
tients who started with dabigatran were assigned to the dabigatran
group and patients who started with acenocoumarol to the acenocou-
marol group. Those patients that were already on VKA before 1 January
2010 and switched to dabigatran during study period were included in
the dabigatran group. From January 2012, dabigatran 150 mg twice a day
(b.i.d.) was preferably prescribed, following reimbursement in the
Netherlands and according to the ESC guideline for the management
of AF. Dabigatran dose was reduced to 110 mg b.i.d. according to renal
function (estimated glomerular filtration rate 30–50 mL/min), concomi-
tant use of verapamil, or age .80 years. Patients who switched from
acenocoumarol discontinued anticoagulation therapy for 2 days (5 half-
lives) and then started dabigatran. Dabigatran was prescribed without
extra compliance counselling. All patients had at least one follow-up visit
after initiating the oral anticoagulation therapy at our outpatient clinic
and were seen every 6–12 months thereafter. There were no exclusion
criteria.
Study outcomes
The primary effectiveness outcome was stroke or systemic embolism.
Primary safety outcome was major bleeding. Secondary effectiveness
outcomes were stroke, transient ischaemic attack (TIA), systemic em-
bolism, myocardial infarction, pulmonary embolism, death from vascular
cause, and death from any cause. Secondary safety outcomes were intra-
cranial bleeding, gastrointestinal bleeding, perioperative bleeding, and
life-threatening bleeding. Stroke was defined as the sudden onset of a
focal neurologic deficit in a location consistent with the territory of a
major cerebral artery caused by an arterial thrombus in this artery, ca-
tegorized as ischaemic stroke and TIA. A TIA was defined as a transient
stroke, whereby clinical symptoms disappeared within 24 h. Systemic
embolism was defined as an acute vascular occlusion of an extremity
or organ, documented by means of imaging, surgery, or autopsy. Death
from vascular cause was defined as death caused by cardiac, haemor-
rhagic, or other vascular pathologic conditions. Major bleeding was de-
fined as an acute bleeding with a sudden reduction in the haemoglobin
level of at least 20 g/L (1.2 mmol/L) or transfusion of at least 2 units of
blood, a symptomatic acute bleeding in a critical area or organ, or an
acute bleeding that required hospitalization. Life-threatening bleeding
was a subcategory of major bleeding that consisted of fatal bleeding,
symptomatic intracranial bleeding, bleeding with a sudden decrease in
the haemoglobin level of at least 50 g/L (3.1 mmol/L), bleeding requiring
transfusion of at least 4 units of blood or inotropic agents, or necessitat-
ing surgery. All other bleedings were considered minor. Intracranial
bleeding consisted of haemorrhagic stroke and subdural or subarach-
noid bleeding. These effectiveness and safety outcome definitions
were based on the definitions used in the RE-LY study.5 For all dabiga-
tran patients, we documented reasons to switch or stop dabigatran
therapy.
In all patients, the CHA2DS2-VASc and HAS-BLED scores at baseline
were calculated.11,12 Individual stroke risk per year at baseline was
adapted from Lip et al., according to the CHA2DS2-VASc scoring sys-
tem.13 Bleeding risk per patient per year was adapted from Pisters
et al., according to the HAS-BLED scoring system.12 The time in thera-
peutic range (TTR) for patient who received acenocoumarol was calcu-
lated according to the Rosendaal method.14
What’s new?
† We compared dabigatran to another vitamin K antagonist
(VKA) than warfarin, i.e. acenocoumarol.
† In ‘real-world’ atrial fibrillation patients, dabigatran is as ef-
fective, but significantly safer than acenocoumarol.
† We show detailed adjustment of endpoints for individual
HAS-BLED and CHA2DS2-VASc scores, in a propensity
score matching design.
† We evaluated switching from VKA therapy to dabigatran in
real life.
† In the current cohort, the HAS-BLED score seems to under-
estimate the bleeding risk on acenocoumarol.
J. Korenstra et al.1320






This study was approved by the Medical Ethics Committee of the Mar-
tini Hospital. Need for informed consent was waived by this Medical
Ethics Committee. Patient data were collected retrospectively from
the electronic patient chart by a single investigator (J.K.) from date da-
bigatran or acenocoumarol was initiated. All effectiveness and safety
outcomes were reviewed by another investigator, blinded for the treat-
ment group (R.G.T.). Potential differences were solved by consensus.
We followed the patients during time on therapy, i.e. until switch to an-
other anticoagulation drug, quitting the anticoagulation drug, death, or a
maximum follow-up duration of 2 years.
Statistical analysis
Variables were described using mean+ standard deviation if distributed
normally or median and range otherwise. Categorical variables were de-
scribed using frequency counts and percentages. Comparative analyses
were performed by using the independent samples t-test, the Mann–
Whitney, or the x2 test, when appropriate.
To address potential selection bias due to the observational non-
randomized study design, we implemented propensity score matching
to achieve a more balanced study cohort. In this, patients treated with
dabigatran were 1:1 matched to patients that received acenocoumarol,
using their probability to receive dabigatran, i.e. the propensity score
for dabigatran. Matching was performed with a 0.1 maximum allowed
difference in the exact propensity scores in a ‘pair of patients’ treated
with dabigatran and acenocoumarol. Propensity score of individual pa-
tients was estimated using multivariable logistic regression with covari-
ates describing condition at baseline. In this, baseline variables related
to general medical conditions, concomitant medication, AF-specific fac-
tors, and risk factors for both stroke and bleeding were liberally
included.
Subsequent analyses were performed using the matched cohort. Sur-
vival analyses were based on the time to first event. Event-free survival
was graphically depicted using the Kaplan–Meier method. In addition,
the Cox proportional hazard regression analysis was applied to examine
whether treatment (dabigatran vs. acenocoumarol) was associated with
the occurrence of the primary effectiveness and safety outcomes. To ac-
count for the potential lack of independence in patients within matched
pairs, robust sandwich estimation of Lin and Wei was applied.
The primary effectiveness outcome analysis was adjusted for the
CHA2DS2-VASc score.
11 The primary safety outcome analysis was ad-
justed for the HAS-BLED score.12 In this, stroke and bleeding risk were
controlled for using the established composite rather than the separate
components of the two risk scores. In addition, other covariates univari-
ately associated (P, 0.10) with the endpoint of interest were consid-
ered for multivariable analysis. Both CHA2DS2-VASc and HAS-BLED
scores were included as categorized variables, as linearity for these
composite variables over categories was not confirmed. We examined
the proportionality hazard assumption by checking if the correlation
coefficient between survival time and the scaled Schoenfeld residuals
was significantly different from zero.
To address a potential healthy-user bias introduced by including ‘VKA
to dabigatran switching’ patients in the dabigatran group, we performed
a sensitivity analysis on the primary effectiveness and safety endpoint
using the matched pairs of patients that were anticoagulation naı¨ve at
the time of initiation of dabigatran and acenocoumarol. For this, the pro-
pensity score matching procedure was repeated in all anticoagulation-
naı¨ve patients from the original cohort.
All analyses were performed using commercially available software
(Statistical Analysis Software, version 9.4, SAS Institute, Cary, NC),
and a two-tailed P-value of ,0.05 was considered statistically significant.
Results
Characteristics of the patients
A total of 920 patients were enrolled, including 442 patients with da-
bigatran and 478 patients with acenocoumarol. Propensity score
matching resulted in 766 matched patients (383 in both groups).
Mean follow-up duration was 1.5+0.56 year. Mean follow-up dur-
ation was 1.3+ 0.54 year in the dabigatran group and 1.8+ 0.46
year in the acenocoumarol group. As presented in Table 1, after
matching, a balanced study cohort was achieved with only limited
differences between the treatment groups. There still was a small
absolute difference in the CHA2DS2-VASc score (3.2 vs. 3.0 in dabi-
gatran vs. acenocoumarol, respectively) mainly due to a difference in
age (70.6 vs. 72.3 years, respectively). Furthermore, beta-blockers
were more frequently used in patients treated with acenocoumarol
and verapamil more frequently used in patients treated with
dabigatran. With regard to the HAS-BLED score, matching resulted
in comparable scores in dabigatran vs. acenocoumarol (mean
HAS-BLED score 1.4 vs. 1.4).
In the dabigatran group, 231 patients received dabigatran 150 mg
b.i.d. and 152 patients received the reduced dose of dabigatran
110 mg b.i.d. Of all dabigatran patients, 23.0% previously received
long-term VKA therapy for at least 2 months.
Primary study outcomes
The mean calculated stroke risk at baseline per year as derived from
the CHA2DS2-VASc score was 3.5% per year in the dabigatran
group vs. 3.7% per year in the acenocoumarol group. The actual in-
cidence rate of stroke or systemic embolismwas 0.8% per year [95%
confidence interval (CI): 0.2–2.0] vs. 1.0% per year (95% CI: 0.4–
2.1), respectively (Table 2, Figure 1). This lower but non-significant
risk in dabigatran vs. acenocoumarol was confirmed in multivariable
analysis resulting in an adjusted hazard ratio (HR) of 0.72 (95% CI
0.20–2.63, P ¼ 0.61) for dabigatran vs. acenocoumarol. In the multi-
variable model, also the a priori stroke risk as assessed by the CHA2-
DS2-VASc score was included. No other baseline variables reached
the level of P, 0.10 set for inclusion in the multivariable model
(Table 3).
The calculated bleeding risk at baseline per year, according to the
HAS-BLED score, was 1.7% per year both groups. The actual inci-
dence rate of major bleeding was 2.1% per year (95% CI: 1.0–3.8)
in the dabigatran vs. 4.3% per year (95% CI: 2.9–6.2) in acenocou-
marol (Table 2, Figure 2). This strongly reduced risk of major bleeding
in dabigatran vs. acenocoumarol was confirmed in multivariable
analysis resulting in an adjusted HR of 0.45 (95% CI: 0.22–0.93,
P ¼ 0.031) for dabigatran vs. acenocoumarol. In the multivariable
model, also the a priori bleeding risk as assessed by the HAD-BLED
score was included. No other baseline variables reached the level of
P, 0.10 set for inclusion in the multivariable model (Table 3).
Secondary outcomes
As presented in Table 4, no significant differences were observed in
the secondary effectiveness endpoints. In patients treated with
dabigatran, a non-significant but slightly higher rate of myocardial
infarction was observed (1.0 vs. 0.6%/year in dabigatran vs.
acenocoumarol, respectively), whereas in patients treated with
Effectiveness and safety of dabigatran versus acenocoumarol 1321
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Age (year) 71.5+9.1 70.6+8.9 72.3+9.3 0.007
Weight (kg) 84.4+17.7 84.3+17.1 84.5+18.4 0.94
Systolic blood pressure (mmHg) 148+23 148+22 147+25 0.27
Diastolic blood pressure (mmHg) 84+13 85+13 84+14 0.24
Male sex, n (%) 401 (52.4) 205 (53.5) 196 (51.2) 0.56
Paroxysmal AF, n (%) 459 (59.9) 231 (60.3) 228 (59.5) 0.10
Persistent AF, n (%) 192 (25.1) 86 (22.5) 106 (27.7)
Permanent AF, n (%) 115 (15.0) 66 (17.2) 49 (12.8)
CHA2DS2-VASc score
b 3.1+1.4 3.0+1.4 3.2+1.3 0.008
1, n (%) 91 (11.9) 57 (14.9) 34 (8.9) 0.021
2, n (%) 189 (24.7) 102 (26.6) 87 (22.7)
3–4, n (%) 371 (48.4) 171 (44.7) 200 (52.2)
5–6, n (%) 104 (13.6) 46 (12.0) 58 (15.1)
7–9, n (%) 11 (1.4) 7 (1.8) 4 (1.0)
CHADS2 score
b 1.7+1.1 1.6+1.2 1.7+1.1 0.008
0–1, n (%) 388 (50.7) 216 (56.4) 172 (44.9) 0.003
2, n (%) 223 (29.1) 92 (24.0) 131 (34.2)
3–6, n (%) 155 (20.2) 75 (19.6) 80 (20.9)
HAS-BLED scoreb 1.4+0.9 1.4+0.9 1.4+0.9 0.84
0–1, n (%) 438 (57.2) 210 (54.8) 228 (59.5) 0.25
2–3, n (%) 315 (41.1) 168 (43.9) 147 (38.4)
4–5, n (%) 13 (1.7) 5 (1.3) 8 (2.1)
Previous stroke, TIA or systemic embolism, n (%) 141 (14.9) 54 (14.1) 60 (15.7) 0.61
Prior myocardial infarction, n (%) 62 (8.1) 30 (7.8) 32 (8.4) 0.89
Prior bleeding, n (%) 55 (7.2) 27 (7.1) 28 (7.3) 1.00
Heart failure or reduced left ventricular ejection fraction, n (%) 120 (15.7) 57 (14.9) 63 (16.5) 0.62
Diabetes mellitus, n (%) 128 (16.7) 61 (15.9) 67 (17.5) 0.63
Hypertension, n (%) 494 (64.5) 246 (64.2) 248 (64.8) 0.94
Abnormal renal function (creatinine clearance ,30), n (%) 7 (1.0) 0 (0.0) 7 (1.9) 0.015
Creatinine (mmol/L) 84.7+38.6 82.6+19.5 86.7+50.4 0.89
Creatinine clearance (mL/min) 73.2+18.8 73.7+17.0 72.7+20.3 0.53
Abnormal liver function (ASAT, ALAT of LD .2 times upper
limit of normal), n (%)
13 (1.8) 7 (2.0) 6 (1.6) 0.78
Alcohol use (≥8 units/week), n (%) 85 (11.1) 37 (9.7) 48 (12.5) 0.25
Concomitant medication, n (%)
Antiplatelet therapy
Single 27 (3.5) 14 (3.7) 13 (3.4) 1.00
Dual 2 (0.3) 1 (0.3) 1 (0.3)
Angiotensin-receptor blocker or ACE inhibitor 482 (62.9) 243 (63.5) 239 (62.4) 0.82
Beta-blocker 520 (67.9) 248 (64.8) 272 (71.0) 0.075
Amiodarone 7 (0.9) 5 (1.3) 2 (0.5) 0.45
Statin 292 (38.1) 152 (39.7) 140 (36.6) 0.41
Proton pump inhibitor 217 (28.3) 104 (27.2) 113 (29.5) 0.52
H2-receptor antagonist 4 (0.5) 2 (0.5) 2 (0.5) 1.00
Verapamil 102 (13.3) 62 (16.2) 40 (10.4) 0.025
Non-steroidal anti-inflammatory drugs 16 (2.1) 7 (1.8) 9 (2.4) 0.80
Previous use of vitamin K antagonist for .2 months, n (%) 88 (11.5) 88 (23.0) –
aPlus–minus values are means+ standard deviation.
bThe CHADS2 score is a measure of the risk of stroke in which congestive heart failure, hypertension, an age of ≥75 years, and diabetes mellitus are each assigned 1 point and
previous stroke or TIA is assigned 2 points. The CHA2DS2-VASc score is a measure of risk of stroke in which congestive heart failure, hypertension, an age of 65–74, diabetes
mellitus, vascular disease, and female sex are each assigned 1 point and previous stroke, TIA or systemic embolism, and age ≥75 are assigned 2 points. The HAS-BLED score is a
measure of the risk of bleeding in which hypertension, abnormal renal function, abnormal liver function, previous stroke, prior bleeding, labile INRs, an age of .65, antiplatelet
therapy or NSAIDs use, and alcohol use are assigned each 1 point.
J. Korenstra et al.1322





acenocoumarol rates of stroke (0.6 vs. 0.9%/year in dabigatran vs.
acenocoumarol, respectively) and death from vascular cause (0 vs.
0.6%/year in dabigatran vs. acenocoumarol, respectively) were
slightly higher.
Rate of total bleeding (major or minor) was significantly lower in
patients receiving dabigatran compared with those who received
acenocoumarol (8.4 vs. 14.2%/year, P ¼ 0.003). For minor bleeds
only, rates were 6.4 vs. 10.0%/year in dabigatran and acenocoumar-
ol, respectively (P ¼ 0.032). Also for the separate components of
the primary safety endpoint of major bleeding, rates were all lower
in the dabigatran group, compared with the acenocoumarol group.
Sensitivity analysis: anticoagulation-naı¨ve
dabigatran vs. acenocoumarol
After propensity score matching using only patients in whom dabi-
gatran was initiated without previous use of a VKA, the matching
procedure resulted in 333 pairs of patients that were all naı¨ve to an-
ticoagulation. Again, matching resulted in a balanced cohort of 666
patients (data not shown). The sensitivity analysis showed a similar
non-significant result with regard to the effectiveness of dabigatran
vs. acenocoumarol in preventing stroke. In this subset of patients, in-
cidence rate of stroke or systemic embolism was 0.7%/year (95% CI:
0.2–2.1) in dabigatran vs. 0.7%/year (95% CI: 0.2–1.7) in acenocou-
marol (HR ¼ 1.2, 95% CI: 0.3–5.2, P ¼ 0.83, for dabigatran vs.
acenocoumarol).
With regard to the primary safety endpoint, a similar significantly
reduced bleeding risk in the dabigatran patients vs. acenocoumarol
was observed [incidence rates 1.9 (95% CI: 0.8–3.8) and 4.6 (95%
CI: 3.0–6.7), HR ¼ 0.39, 95% CI: 0.18–0.86, P ¼ 0.019, for dabiga-
tran vs. acenocoumarol].
Furthermore, there was no relation between the dose of dabiga-
tran and outcome. None of the patients who switched from a VKA
to dabigatran suffered from a stroke or systemic embolism, or major
bleeding in the first week following change of anticoagulation
therapy.
Time in therapeutic range
In the patients treated with acenocoumarol, the TTR according to
the Rosendaal method14 was assessed using available INR data.
The therapeutic range was defined as INR 2.0–3.5, as this range is
routinely applied in the Netherlands. With a mean TTR of 78.0%
(9.4% below and 12.6% above this range), overall level of anticoagu-
lation was good. A poor level of anticoagulation, i.e. TTR , 45%,
was only observed in 5.5% of patients. When considering a nar-
rower range of INR between 2.0 and 3.0 TTR reduced to 55.0%
(9.4% below and 35.6% above this range). The individual INR at
the time of event was not related to the occurrence of stroke orma-
jor bleeding. Furthermore, therewas no significant relation between
the individual TTR and outcome.
Discussion
To date, two large database studies in Denmark and the USA exam-
ined the real-world experience of dabigatran compared with war-
farin, and one study examined NOACs (mainly dabigatran) based
on examination of individual patient records in Sweden.15 –17 All
these studies confirmed the results from the RE-LY study in which
dabigatran 150 mg b.i.d. demonstrated improved efficacy and non-
inferior safety as compared with warfarin.5 In Figure 3, it is shown
that the present study demonstrated the lowest stroke rates com-
pared with the other studies, presumably due to a relatively healthy
AF population. This is illustrated by an average CHADS2 score of 1.7
in the present study vs. 2.1 in the RE-LY study. The dabigatran pa-
tients in the present study also demonstrate a low bleeding rate.
In contrast, despite the same definition of major bleeds, bleeding
rate in the acenocoumarol patients was amongst the highest scores.
Furthermore, in our study, bleeding rate in the dabigatran patients
was in line with that what was predicted from the HAS-BLED score,
whereas bleeding rate in the acenocoumarol patients was much
higher than expected from the HAS-BLED score. In part, this may
be explained by a different target INR range than previously used
in the trials with warfarin. Traditionally, in the Netherlands, the
Thrombosis Service aims at an INR between 2.0 and 3.5, while
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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aCalculated stroke risk according to the CHA2DS2-VASc score.
bCalculated bleeding risk according to the HAS-BLED score.
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Figure 1 The Kaplan–Meier survival curve of dabigatran vs. ace-
nocoumarol for stroke or systemic embolism.
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the RE-LY study followed the international guidelines with an ad-
vised INR level between 2.0 and 3.0 for stroke prevention in AF.2
Furthermore, acenocoumarol has a shorter half-life than warfarin.
Higher INRs are thereby more easy to counteract, but it may also
result in more labile INR values, especially towards the higher end
of the therapeutic range. Indeed, aiming for an INR of 2.0–3.5 re-
sulted in a TTR of 78.0%, but the TTR between 2.0 and 3.0 was
only 55.0%. This is much lower than the TTR on warfarin in the
RE-LY study (64%).5 Using the stricter target INR between 2.0
and 3.0 could result in a higher TTR in patients on acenocoumarol
and may lead to a lower rate of events. On the other hand, it has
been described that only a TTR of ,45% was associated with
poor outcome in patients treated with acenocoumarol.18 In our
study, poor TTR was observed in only a very limited number of pa-
tients possibly explaining the absence of an association between
individual TTR and the occurrence of a stroke or bleeding. This is
in line with previous reports showing that TTR is a poor predictor
of clinical outcomes.19 Furthermore, no association was observed
with the INR values at the time of event.
Although the majority of the dabigatran patients in our study re-
ceived dabigatran in a dose of 150 mg b.i.d., we found non-inferior
effectiveness rates and superior safety rates of dabigatran, compared
with acenocoumarol. This observation is in contrast to the RE-LY
trial, where superior effectiveness rates and non-inferior safety rates
were found for dabigatran dosed at 150 mg b.i.d., when compared
with warfarin. On one hand, this may be due to the higher bleeding
rates on acenocoumarol than expected. On the other hand, our low
reported bleeding rate of dabigatran may be a reflection of the ap-
plication of prescribing recommendations and guidelines, whereby
the 150 mg dose dabigatran was not administered in elderly patients
(age ≥80 years), in patients at high bleeding risk, using concomitant
interacting drugs (e.g. verapamil) or in patients with a moderate re-
nal impairment (CrCl 30–49 mL/min). In these patients, the ad-
justed dose of dabigatran 110 mg was recommended.9
One of the most dramatic complications of oral anticoagulation
therapy is intracranial bleeding, especially haemorrhagic stroke. In
our study, none of the patients with dabigatran got an intracranial
bleeding, compared with 0.3%/year in patients with acenocoumarol,
without a reduction in the effectiveness against ischaemic stroke.
Although the sample size of the study has insufficient power to ana-
lyse this difference, it is in line with the results from the randomized
trials comparing the different NOACs with warfarin, in which intra-
cranial bleeding rates were also lower in patients using the
NOACs.5–8 Also all other crude rates of bleeding, including gastro-
intestinal bleeding, were lower with dabigatran, compared with ace-
nocoumarol (Table 4).
In a sensitivity analysis, we compared the primary effectiveness and
safety outcomes of anticoagulation-naı¨ve dabigatran with acenocou-
marol.We show that also in anticoagulation-naı¨ve patients, dabigatran
was associated with significant less major bleeding events when
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Table 3 Results from multivariate analysis
Crude Adjusted
HR 95% CI P-value HR 95% CI P-value
Stroke or systemic embolism
Dabigatran treatment 0.73 0.21–2.55 0.62 0.72 0.20–2.63 0.61
CHA2DS2-VASc score
a
1–4 – – 0.067 – – 0.066
5–6 2.69 0.71–10.3 2.64 0.69–10.1
6–9 9.14 1.13–74.1 9.59 1.13–81.7
Major bleeding
Dabigatran treatment 0.44 0.21–0.93 0.032 0.45 0.22–0.93 0.031
HAS-BLED scoreb
0–1 – – 0.028 – – 0.031
2 0.94 0.46–1.96 0.98 0.48–2.02
3–4 2.78 1.24–6.23 2.79 1.24–6.26
aThe CHA2DS2-VASc score was categorized into three score classes, as linearity was not established.
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Figure 2 The Kaplan–Meier survival curve of dabigatran vs.
acenocoumarol for major bleeding.
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Table 4 Secondary effectiveness and safety outcomes, according to treatment group.a
Event Dabigatran (N 5 383) Acenocoumarol (N 5 383) Dabigatran vs. acenocoumarol
No. of patients %/year No. of patients %/year P-value*
Secondary effectiveness outcomes
Stroke or systemic embolism 4 0.8 7 1.0 0.61
Stroke 3 0.6 6 0.9 0.50
Ischaemic stroke 2 0.4 3 0.4 0.77
TIA 1 0.2 3 0.4 0.52
Systemic embolism 1 0.2 1 0.1 0.73
Myocardial infarction 5 1.0 4 0.6 0.35
Pulmonary embolism 0 0.0 0 0.0 –
Death from vascular cause 0 0.0 4 0.6 NE
Death from any cause 10 2.0 11 1.6 0.83
Secondary safety outcomes
Major bleeding 10 2.1 28 4.3 0.031
Life-threatening 1 0.2 6 0.9 0.17
Gastrointestinalb 1 0.2 5 0.7 0.24
Perioperativeb 8 1.6 15 2.3 0.42
Minor bleeding 30 6.4 62 10.0 0.032
Major or minor bleeding 39 8.4 84 14.2 0.003
Intracranial bleeding 0 0.0 2 0.3 NE
aData are shown for all patients who had at least one event. All calculations were based on the time to the first event.
bSome gastrointestinal and perioperative bleedings were life-threatening and are included in both categories.
NE; not estimable due to zero counts and/or small numbers.












































Figure 3 Effectiveness and safety outcomes of ‘real-world’ registries investigating stroke prevention in AF by dabigatran vs. vitamin K antagonists
in relation to the randomized RE-LY trial. *VKA: warfarin in all studies, except for the Netherlands; acenocoumarol. †Dabigatran in a dose of
150 mg b.i.d. in all studies, except for the USA (150 or 75 mg b.i.d.); and the Netherlands (all doses).
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comparedwith acenocoumarol. Furthermore, we found no significant
difference in safety between the anticoagulation-naı¨ve dabigatran pa-
tients and the patients who initiated dabigatran after long-term VKA
therapy. In short, previous use of anticoagulation therapy does not
seem to have an influence on our primary results. The protocol which
we used for switching VKA therapy to dabigatran appeared to be safe.
Because in randomized trials all NOACs provide an improved ef-
ficacy/safety ratio, and are more convenient to use when compared
with warfarin, they are recommended as broadly preferable to
VKAs in the 2012 updated ESC guideline for the management of
AF. However, concerns have been raised about presumed excess
of bleeding events on dabigatran.20 In our ‘real-world’ investigation,
we found no evidence for an excess of bleeding events among
patients treated with dabigatran. In fact, patients treated with dabi-
gatran experienced less than half the rate of major bleedings per
year as patients treated with acenocoumarol (HR ¼ 0.45, 95%
CI: 0.22–0.93, P ¼ 0.031). Our conclusions are in line with the ran-
domized trials and other registries, also showing an improved effect-
iveness/safety ratio of dabigatran.
Study limitations
Because this was a retrospective study, significant differences ex-
isted between study groups. According to the ESC guideline,9
from 2012 on, we preferably prescribed NOACs, unless patients
had a poor renal function or were at very old age. In these cases,
a VKA was prescribed. This might have led to a selection bias,
whereby the acenocoumarol group is probably more fragile com-
pared with the dabigatran patients. To address this issue, we per-
formed propensity score matching to achieve a more balanced
cohort, based on estimated probabilities for receiving dabigatran/
acenocoumarol. Although selection bias cannot be fully excluded,
our treatment groups were highly comparable after matching.
With respect to poor renal function in our study population only se-
ven patients had an abnormal renal function (Table 1). Furthermore,
we included the CHA2DS2-VASc and HAS-BLED scores in our Cox
regression model to correct for any remaining confounding due to
differences in a priori risk status. Follow-up duration was significant-
ly different between the two patient groups; therefore, events were
described in per cent per year. The Cox regression model used for
comparing the two treatment groups adjusts for differences in
follow-up duration by using the time till first event.
Furthermore, this was a single-centre investigation, and the sam-
ple size was too small to study the secondary outcomes with suffi-
cient power. Data were retrieved from our institution’s electronic
patient records. Events that occurred in other hospitals or at
home might be missing, but this is true for both treatment groups.
Finally, we had no special service to ensure compliance. On the
other hand, this may resemble real-life NOAC use in general. In
our clinic, every new patient with AF is informed about the risk of
stroke and thromboembolism and is advised to adhere to the pre-
scribed anticoagulation regimen.
Conclusion
The present study compared effectiveness and safety outcomes of
dabigatran and acenocoumarol in patients with non-valvular AF. We
showed that dabigatran was associated with significantly lower rates
of major bleeding with a comparable rate of stroke or systemic em-
bolism comparedwith acenocoumarol. We therefore conclude that
dabigatran in daily clinical practice in patients with AF appears to be
as effective, but significantly safer than acenocoumarol.
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A useful irrigated tip to cannulate distal coronary sinus
J. Fedida, C. Lepiece, and S. Knecht
A 69-year-old man was referred to our centre
for an ablation procedure of symptomatic ven-
tricular ectopics with left bundle branch block
morphology, inferior axis, and transition in
lead V2 suggesting a left ventricle outflow tract
origin.
Using a 3D Cartow mapping system and an
irrigated-tip ablation catheter (Thermocoolw SF,
Biosensew), pace-mapping from the left ventricu-
lar outflow tract rose to 88% of correlation in the
left coronary cusp. An attempt was then made to
cannulate the distal coronary sinus (CS) with a
long sheath to stabilize the catheter but was im-
possible distally from the lateral mitral annulus
despite multiple attempts (Panel A). A high-flow
saline perfusion, 60 mL/min at room temperature
during an arbitrary period of 2 min, was ad-
ministered via the ablation catheter in the distal
CS. Advancing further the ablation catheter
was then successfully carried out (Panel A). At
this location, in front of the left coronary cusp,
pace-mapping showed a correlation of 98.5%
(Panel B).
Distal CS cannulation may be challenging
mainly because of the presence of a Vieussens
valve or a small distal vein. However, the origin
of a focus can be epicardial and only reachable
via the very distal CS. High-flow irrigation may
help its cannulation probably by increasing CS
volume allowing dilatation and therefore
accessibility for the catheter.
The full-length version of this report can be viewed at: http://www.escardio.org/Guidelines-&-Education/E-learning/Clinical-cases/
Electrophysiology/EP-Case-Reports.
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